Background Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and ultimately fatal disease. An association between diabetes, obesity and IPF has previously been demonstrated.
Introduction Idiopathic Pulmonary Fibrosis (IPF) is a debilitating lung disease with average life expectancy of 3-5 years. IPF services in England, commissioned by NHS England, occur in a finite number of designated specialist centres. With the advent of antifibrotics early referral is paramount to impact disease pathogenesis. Inequalities in UK healthcare have been documented in lung disease. Our objective was to assess whether we received the expected number of referrals compared to the NICE predicted disease prevalence (0.0277%). 1 Methods This is a single centre review of University Hospital of South Manchester (UHSM) British Thoracic Society (BTS) entries from 2013 to 2017. Patient's entry postcodes were mapped to individual clinical commissioning groups (CCG). IPF patients within each CCG were compared to the expected disease prevalence (0.0277%). Results UHSM is the largest contributor to the BTS-IPF registry with 457 of the total 1119 patient record (41%). 451 patients from 35 English CCGs were represented. 6 patients were from outside England (Wales and Isle of Man). There are two specialist centres in the North West, Aintree and UHSM. 13 CCGs are located geographically closest to Aintree and 14 closest to UHSM with a further 8 CCGs located equidistant. Patients are referred to either specialist service at the discretion of the clinician and patient preference. The expected number of patients seen at UHSM according to IPF prevalence varied greatly in the 14 CCGs geographically closest with an average of 19 referrals per CCG (range 3-37) compared to the expected 51 referrals. CCGs varied in their referral rates with the top three CCGs Trafford (71%), Tameside and Glossop (65%) and Salford (54%) and the lowest referrals from Central (6%) and North Manchester (19%) ( Table 1) . Background Idiopathic pulmonary fibrosis (IPF) is a rare disease, and estimates of incidence and prevalence vary considerably by geographic region. There have been few studies of patient populations with IPF in Sweden and here we describe the first national cohort of patients with pulmonary fibrosis. Methods A retrospective longitudinal study with linked datasets from Swedish population-based registers and electronic medical records from 2001-2017. Included patients had a registration of International Classification of Diseases, Tenth Revision (ICD-10) code J84.1, were aged 40 years and did not have a competing diagnosis after the initial J84.1 code; a diagnosis algorithm was used to refine the population for patients with IPF. This national cohort was based on linked patient-level data from national, population-based health registers. Objectives To describe incidence of pulmonary fibrosis and clinical characteristics (comorbidities and concomitant medications) at diagnosis and at any time. Results Cohort 1 included 17 244 patients with pulmonary fibrosis. Incidence of pulmonary fibrosis ranged from 10.4-15.4 cases per 1 00 000 per year between 2001 and 2015, with an incidence of 13.9 cases per 1 00 000 per year in 2015. Incidence increased with age and was higher in males. Patients had a mean (standard deviation [SD]) age of 74.6 (10.5) years at time of diagnosis and 62.5% were male. Clinical characteristics of these patients are shown in the table; patients had a mean (SD) Charlson comorbidity index of 1.4 (1.7).
Abstract P148 Table 1 CCGs geographically situated next to UHSM. Data demonstrates patients expected according to disease prevalance, actual number of referred and their according percentages
